NR3C1 and muscular dystrophy: The development of the dissociative steroid vamorolone in mdx mice shows that a GR ligand can improve muscle function and pathology in muscular dystrophy without prednisone-like side effects of impaired growth or immunosuppression (Heier et al., 2013, 2019); consistent results are now being seen in human trials, in which vamorolone improves DMD outcomes with greatly reduced side effects to growth and bone (Hoffman et al., 2019; Mah et al., 2022; Smith et al., 2020; Dang et al., 2024).